Key result
Low irisin levels linked to ~20% higher ADHF risk in patients with T2D and HF.
Why the study?
The discriminative value of irisin for predicting acutely decompensated heart failure in type 2 diabetes mellitus patients with chronic heart failure was unclear.
Do low serum irisin levels predict acutely decompensated heart failure in patients with type 2 diabetes mellitus and chronic heart failure?
Cohort (n=480)
Do low serum irisin levels predict acutely decompensated heart failure in patients with type 2 diabetes mellitus and chronic heart failure?
Decreased serum irisin levels (<7.85 ng/mL) independently predict acutely decompensated heart failure in patients with chronic heart failure and type 2 diabetes mellitus, providing incremental prognostic value beyond NT-proBNP.
Answers are grounded in this paper and cite their sources.
May aid ADHF risk stratification in T2DM with chronic HF; leaves open clinical utility pending prospective validation.
The aim of this study was to determine the discriminative value of irisin for acutely decompensated heart failure (ADHF) in type 2 diabetes mellitus (T2DM) patients with chronic HF. We included 480 T2DM patients with any phenotype of HF and followed them for 52 weeks. Hemodynamic performances and the serum levels of biomarkers were detected at the study entry. The primary clinical end-point was ADHF that led to urgent hospitalization. We found that the serum levels of N-terminal natriuretic pro-peptide (NT-proBNP) were higher (1719 [980–2457] pmol/mL vs. 1057 [570–2607] pmol/mL, respectively) and the levels of irisin were lower (4.96 [3.14–6.85] ng/mL vs. 7.95 [5.73–9.16] ng/mL) in ADHF patients than in those without ADHF. The ROC curve analysis showed that the estimated cut-off point for serum irisin levels (ADHF versus non-ADHF) was 7.85 ng/mL (area under curve [AUC] = 0.869 (95% CI = 0.800–0.937), sensitivity = 82.7%, specificity = 73.5%; p = 0.0001). The multivariate logistic regression yielded that the serum levels of irisin < 7.85 ng/mL (OR = 1.20; p = 0.001) and NT-proBNP > 1215 pmol/mL (OR = 1.18; p = 0.001) retained the predictors for ADHF. Kaplan–Meier plots showed a significant difference of clinical end-point accumulations in patients with HF depending on irisin levels (<7.85 ng/mL versus ≥7.85 ng/mL). In conclusion, we established that decreased levels of irisin were associated with ADHF presentation in chronic HF patients with T2DM independently from NT-proBNP.
No takes yet. Share an insight, caveat, or question.
Berezin et al. (2023) conducted a cohort in Type 2 diabetes mellitus with chronic heart failure (n=480). Decreased serum irisin levels (< 7.85 ng/mL) vs. Serum irisin levels ≥ 7.85 ng/mL was evaluated on Acutely decompensated heart failure (ADHF) that led to urgent hospitalization (OR 1.20, p=0.001). Decreased serum irisin levels independently predicted acutely decompensated heart failure in patients with type 2 diabetes and chronic heart failure.
Synapse has enriched 10 related papers. Consider them for comparative context: